2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
Evaluation of the effectiveness of a new system HD2/NBI2 to improve the detection of colorectal neoplastic lesions during colonoscopy in comparison to the former generation with currently highest share of the installed base (nonHD-nonNBI system i.e…